Circulating MACC1 Transcripts in Colorectal Cancer Patient Plasma Predict Metastasis and Prognosis

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Stein, Ulrike ^a   Burock, Susen ^a   Herrmann, Pia ^a   Wendler, Ina ^a   Niederstrasser, Markus ^a   Wernecke, Klaus Dieter ^a   Schlag, Peter M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CALVASCULIN; METASTASIS ASSOCIATED IN COLON CANCER 1 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS ASSOCIATED IN COLON CANCER 1 GENE; NON INVASIVE PROCEDURE; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S100A4 GENE; SENSITIVITY AND SPECIFICITY; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; S100 PROTEINS; STATISTICS, NONPARAMETRIC; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869108102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049249     Document Type: Article

References (50)

1. Stein U, Walther W, Arlt F, Schwabe H, Smith J, et al. (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15: 59-67.
2. Arlt F, Stein U, (2009) Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol 41: 2356-2359.
3. Stein U, Dahlmann M, Walther W, (2010) MACC1- more than metastasis? Facts and predictions about a novel gene. J Mol Med 88: 11-18.
4. Stein U, Smith J, Walther W, Arlt F, (2009) MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle 8: 2467-2469.
5. Shirahata A, Shinmura K, Kitamura Y, Sakuraba K, Yokomizo K, et al. (2010) MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res 30: 2689-2692.
6. Galimi F, Torti D, Sassi F, Isella C, Corà D, et al. (2011) Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res 17: 3146-3156.
7. Wiśniewski JR, Ostasiewicz P, Mann M, (2011) High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J Proteome Res 10: 3040-3049.
8. Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, et al. (2012) MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res 18: 737-747.
9. Lang AH, Geller-Rhomberg S, Winder T, Stark N, Gasser K, et al. (2012) A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients. BMC Cancer 12: 20.
10. Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, et al. (2010) MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res 30: 3441-3444.
11. Chundong G, Uramoto H, Onitsuka T, Shimokawa H, Iwanami T, et al. (2011) Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res 31: 1141-1145.
12. Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, et al. (2011) Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg 141: 895-898.
13. Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, et al. (2011) MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res 31: 777-780.
14. Qiu J, Huang P, Liu Q, Hong J, Li B, et al. (2011) Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med 9: 166.
15. Zhang R, Shi H, Chen Z, Wu Q, Ren F, et al. (2011) Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. J Exp Clin Cancer Res 30: 83.
16. Stein U, Arlt F, Walther W, Smith J, Waldman T, et al. (2006) The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology 131: 1486-1500.
17. Boye K, Maelandsmo GM, (2010) S100A4 and metastasis: a small actor playing many roles. Am J Pathol 176: 528-535.
18. Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, et al. (2011) Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients. J Mol Diagn 13: 189-198.
19. Schwarzenbach H, Hoon DS, Pantel K, (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426-437.
20. El-Hefnawy T, Raja S, Kelly L, Bigbee WL, Kirkwood JM, et al. (2004) Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem 50: 564-573.
21. Barzon L, Boscaro M, Pacenti M, Taccaliti A, Palu G, (2004) Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse. Int J Cancer 110: 914-920.
22. Goebel G, Zitt M, Zitt M, Müller HM, (2005) Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 21: 105-120.
23. Miura N, Nakamura H, Sato R, Tsukamoto T, Harada T, et al. (2006) Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci 97: 1366-1373.
24. Fleischhacker M, Schmidt B, (2007) Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 1775: 181-232.
25. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, et al. (2007) Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56: 782-789.
26. Tani N, Ichikawa D, Ikoma D, Tomita H, Sai S, et al. (2007) Circulating cell-free mRNA in plasma as a tumor marker for patients with primari and recurrent gastric cancer. Anticancer Res 27: 1207-1212.
27. O'Driscoll L, Kenny E, Mehta JP, Doolan P, Joyce H, et al. (2008) Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR. Cancer Genomics Proteomics 5: 94-104.
28. Garcia V, García JM, Peña C, Silva J, Domínguez G, et al. (2008) Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett 263: 312-320.
29. Zhang X, Wang C, Wang L, Du L, Wang S, et al. (2012) Detection of circulating Bmi-1 mRNA in plasma and its potential diagnostic and prognostic value for uterine cervical cancer. Int J Cancer 131: 165-172.
30. Cocucci E, Racchetti G, Meldolesi J, (2009) Shedding microvesicles: artefacts no more. Trends Cell Biol 19: 43-51.
31. Orozco AF, Lewis DE, (2010) Flow cytometric analysis of circulating microparticles in plasma. Cytometry A 77: 502-514.
32. García JM, García V, Peña C, Domínguez G, Silva J, et al. (2008) Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA 14: 1424-1432.
33. Lledo SM, Garcia-Granero E, Dasi F, Ripoli R, García SA, et al. (2004) Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer. Colorectal Dis 6: 236-242.
34. Wong SC, Lo SF, Cheung MT, Ng KO, Tse CW, et al. (2004) Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clinical Cancer Res 10: 1613-1617.
35. Garcia V, Garcia JM, Pena C, Silva J, Domínguez G, et al. (2006) Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clinical Cancer Res 12: 2095-2100.
36. Garcia JM, Peña C, Garcia V, Domínguez G, Muñoz C, et al. (2007) Prognostic value of LISCH7 mRNA in plasma and tumor of colon cancer patients. Clinical Cancer Res 13: 6351-6357.
37. Silva JM, Rodriguez R, Garcia JM, Muñoz C, Silva J, et al. (2002) Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 50: 530-534.
38. Goldstein MJ, Mitchell EP, (2005) Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 23: 338-351.
39. Wang JY, Lin SR, Wu DC, Lu CY, Yu FJ, et al. (2007) Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clinical Cancer Res 13: 2406-2413.
40. Nielsen HJ, Brünner N, Jorgensen LN, Olsen J, Rahr HB, et al. (2011) Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol. 46: 60-69.
41. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, et al. (2011) Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 6: e17745.
42. Helfman DM, Kim EJ, Lukanidin E, Grigorian M, (2005) The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 92: 1955-1958.
43. Garrett SC, Varney KM, Weber DJ, Bresnick AR, (2006) S100A4, a mediator of metastasis. J Biol Chem 281: 677-680.
44. Takenaga K, Nakanishi H, Wada K, Suzuki M, Matsuzaki O, et al. (1997) Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. Clinical Cancer Res 3: 2309-2316.
45. Gongoll S, Peters G, Mengel M, Piso P, Klempnauer J, et al. (2002) Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 123: 1478-1484.
46. Cho YG, Kim CJ, Nam SW, Yoon SH, Lee SH, et al. (2005) Overexpression of S100A4 is closely associated with progression of colorectal cancer. World J Gastroenterol 11: 4852-4856.
47. Hemandas AK, Salto-Tellez M, Maricar SH, Leong AF, Leow CK, (2006) Metastasis-associated protein S100A4-a potential prognostic marker for colorectal cancer. J Surg Oncol 93: 498-503.
48. Kim JH, Kim CN, Kim SY, Lee JS, Cho D, et al. (2009) Enhanced S100A4 protein expression is clinicopathologically significant to metastatic potential and p53 dysfunction in colorectal cancer. Oncol Rep 22: 41-47.
49. Stein U, Smith J, Walther W, Arlt F, (2009) MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle 8: 2467-2469.
50. Gherardi E, Birchmeier W, Birchmeier C, Woude GV, (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12: 89-103.